May 6 (Reuters) - Australian biotech firm CSL Ltd (CSL) said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus.
The company's unit CSL Behring will develop the immunoglobulin product at its Melbourne-based Broadmeadows facility using antibodies from plasma collected from people who have recovered from COVID-19, CSL said in a statement on its website.
CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said.
- Forums
- ASX - By Stock
- News: CSL Australia's CSL to start work on immunoglobulin product to treat COVID-19
May 6 (Reuters) - Australian biotech firm CSL Ltd (CSL) said on...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$305.54 |
Change
-4.850(1.56%) |
Mkt cap ! $147.6B |
Open | High | Low | Value | Volume |
$307.68 | $309.50 | $305.54 | $259.6M | 847.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 640 | $305.54 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$306.30 | 200 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 20 | 305.500 |
1 | 2854 | 305.450 |
1 | 727 | 305.380 |
1 | 659 | 305.290 |
1 | 595 | 305.160 |
Price($) | Vol. | No. |
---|---|---|
306.770 | 230 | 4 |
307.220 | 917 | 2 |
307.390 | 73 | 1 |
307.410 | 917 | 1 |
307.540 | 2854 | 1 |
Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |